Statins modulate the mortality risk associated with obesity and cardiorespiratory fitness in diabetics

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 3394-3401

  Nylén, Eric S ^a   Faselis, Charles ^a   Kheirbek, Raya ^a   Myers, Jonathan ^c   Panagiotakos, Demosthenes ^d   Kokkinos, Peter ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d HAROKOPIO UNIVERSITY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; EXERCISE TOLERANCE; FITNESS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY SYSTEM; SURVIVAL; UNITED STATES; VETERAN;

AGED; BODY MASS INDEX; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC EQUIVALENT; MIDDLE AGED; OBESITY; PHYSICAL FITNESS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK;

EID: 84881494750     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1431     Document Type: Article

References (37)

1. Heart Protection Study Collaborative Group, Bulbulia R, Bowman L, Wallendszus K, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20, 536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378:2013-2020.
2. Gregg EW, Cheng YJ, Narayan KM, et al. The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976-2004. Prev Med. 2007; 45:348-352.
3. Kokkinos P, Myers J, Nylen E, et al. Exercise capacity and all-cause mortality in African American and Caucasian men with type 2 diabetes. Diabetes Care. 2009;32:623-628.
4. Executive summary: standards of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl 1):S4-S10.
5. Colberg SR, Sigal RJ, Fernhall B, et al; American College of Sports Medicine, American Diabetes Association. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care. 2010; 33:e147-e167.
6. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Int Med. 2012;172:144-152.
7. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
8. Urso ML, Clarkson PM, Hittel D, et al. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol. 2005;25:2560-2566.
9. Bouitbir J, Daussin F, Charles AL, et al. Mitochondria of trained skeletal muscle are protected from deleterious effects of statins. Muscle Nerve. 2012;46:367-373.
10. Golomb BA Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172:1180-1182.
11. Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012;e001472.
12. Mascitelli L, Pezzetta, F. Physical activity in statin-treated patients. Int J Cardiol. 2009;134:136-137.
13. Kokkinos P, Myers J, Faselis C, Doumas M, et al. BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. Diabetes Care. 2012;35:1021-1027.
14. Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes.JAMA. 2012;308:581-590.
15. Kokkinos PF, Faselis C, Myers J, et al. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet. 2013;381:394-399.
16. Boyle CA, Decouflé P. National sources of vital status information: extent of coverage and possible selectivity in reporting. Am J Epidemiol. 1990;131:160-168.
17. Myers J, Buchanan N, Walsh D, et al. Comparison of the ramp versus standard exercise protocols. J Am Coll Cardiol. 1991;17: 1334-1342.
18. American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. 6th ed. Baltimore, MD: Lippincott Williams, Wilkins; 2000.
19. Gibbons RJ, Balady GJ, Bricker JT, et al; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation. 2002; 106:1883-1892.
20. Morris CK, Myers J, Froelicher VF, et al. Nomogram based on metabolic equivalents and age for assessing aerobic exercise capacity in men. J Am Coll Cardiol. 1993;22:175-182.
21. McAuley PA, Blair SN. Obesity paradoxes. J Sports Sci. 2011;29: 773-782.
22. Zheng W, McLerran DF, Rolland B, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011;364:719-729.
23. Azimi A, CharlotMG, Torp-Pedersen C, et al. Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. Heart. 2013;99:655-660.
24. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of allcause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71-82.
25. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 suppl 1)III39 -III43.
26. Conus F, Rabasa-Lhoret R, Péronnet F. Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab. 2007;32:4-12.
27. Kim TN, Park MS, Yang SJ, et al. Body size phenotypes and low muscle mass: The Korean sarcopenic obesity study (KSOS). J Clin Endocrinol Metab. 2013;98:811-817.
28. Zhang L, Gong D, Li S, Zhou X. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis. 2012;223:78-85.
29. Bellia A, Rizza S, Lombardo MF, Donadel G, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis. 2012;223:197-203.
30. Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012; 40:188-194.
31. Meex RC, Phielix E, Schrauwen-Hinderling VB, et al. The use of statins potentiates the insulin-sensitizing effect of exercise training in obese males with and without type 2 diabetes. Clin Sci. 2010;119: 293-301.
32. Centers for Disease Control and Prevention. State indicator report on physical activity, 2010. Atlanta, GA: U.S. Department of Health and Human Services; 2010.
33. Fang ZY, Sharman J, Prins JB, Marwick TH. Determinants of exercise capacity in patients with type 2 diabetes. Diabetes Care. 2005; 28:1643-1648.
34. Morrato EH, Hill JO, Wyatt HR, et al. Physical activity in U.S. adults with diabetes and at risk for developing diabetes, 2003. Diabetes Care. 2007;30:203-209.
35. Kizer KW, Demakis JG, Feussner JR. Reinventing VA health care: systematizing quality improvement and quality innovation. Med Care. 2000;38(6 Suppl 1):I7-I16.
36. Selim AJ, Berlowitz DR, Fincke G, et al. Risk-adjusted mortality rates as a potential outcome indicator for outpatient quality assessments. Med Care. 2002;40:237-245.
37. McAuley PA, Kokkinos PF, Oliveira RB, Emerson BT, Myers JN Obesity paradox and cardiorespiratory fitness in 12, 417 male veterans aged 40 to 70 years. Mayo Clin Proc. 2010;85:115-121.